company background image
0RA9 logo

ABIVAX Société Anonyme LSE:0RA9 Stock Report

Last Price

€13.58

Market Cap

€852.9m

7D

7.8%

1Y

103.0%

Updated

24 Mar, 2024

Data

Company Financials +

ABIVAX Société Anonyme

LSE:0RA9 Stock Report

Market Cap: €852.9m

0RA9 Stock Overview

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.

0RA9 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ABIVAX Société Anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ABIVAX Société Anonyme
Historical stock prices
Current Share Price€13.58
52 Week High€19.58
52 Week Low€6.79
Beta1.48
1 Month Change15.20%
3 Month Change37.37%
1 Year Change103.00%
3 Year Change-32.10%
5 Year Change52.60%
Change since IPO86.96%

Recent News & Updates

Recent updates

Shareholder Returns

0RA9GB BiotechsGB Market
7D7.8%3.2%2.4%
1Y103.0%-27.1%4.2%

Return vs Industry: 0RA9 exceeded the UK Biotechs industry which returned -26.2% over the past year.

Return vs Market: 0RA9 exceeded the UK Market which returned 4.9% over the past year.

Price Volatility

Is 0RA9's price volatile compared to industry and market?
0RA9 volatility
0RA9 Average Weekly Movement8.1%
Biotechs Industry Average Movement7.9%
Market Average Movement4.7%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0RA9's share price has been volatile over the past 3 months.

Volatility Over Time: 0RA9's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
201326Marc M. de Garidelhttps://www.abivax.com

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme Fundamentals Summary

How do ABIVAX Société Anonyme's earnings and revenue compare to its market cap?
0RA9 fundamental statistics
Market cap€852.85m
Earnings (TTM)-€91.51m
Revenue (TTM)€20.00k

Over9,999x

P/S Ratio

-9.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RA9 income statement (TTM)
Revenue€20.00k
Cost of Revenue€0
Gross Profit€20.00k
Other Expenses€91.53m
Earnings-€91.51m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 02, 2024

Earnings per share (EPS)-1.45
Gross Margin100.00%
Net Profit Margin-457,550.00%
Debt/Equity Ratio50.1%

How did 0RA9 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.